EU/LA Pearl Index Study - Transdermal Contraceptive Patch

PHASE3CompletedINTERVENTIONAL
Enrollment

1,694

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Contraception
Interventions
DRUG

Ethinylestradiol/Gestodene (BAY86-5016)

7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

Trial Locations (66)

1824

Lanús Oeste

2000

Rosario

2031

Ashfield

3168

Clayton

5000

Adelaide

5006

North Adelaide

6009

Nedlands

10247

Berlin

10700

México D.F.

11000

Mexico City

México, D.F.

11100

San Fernando

12587

Berlin

13507

Berlin

21800

Quetigny

27000

Torreón

27002

Lugo

27100

Pavia

30029

Nîmes

31000

Toulouse

31015

Pamplona

31350

Chihuahua City

36209

Vigo

38889

Blankenburg

39104

Magdeburg

40138

Bologna

41124

Modena

41700

Dos Hermanas

42103

Wuppertal

45200

Montargis

50001

Zaragoza

50134

Florence

50924

Cologne

51092

Reims

52072

Aachen

53100

Siena

56126

Pisa

57072

Siegen

60590

Frankfurt am Main

64200

Biarritz

72021

Francavilla Fontana

78100

Saint-Germain-en-Laye

78230

San Luis Potosí City

88100

Catanzaro

90127

Palermo

4790711

Temuco

4791348

Temuco

7510025

Santiago

8320165

Santiago

8350488

Santiago

B1642CLN

San Isidro

C1280AEB

Buenos Aires

C1425ASQ

Buenos Aires

C1425AWC

Buenos Aires

01744

Dippoldiswalde

01099

Dresden

04207

Leipzig

04299

Leipzig

06917

Jessen

07545

Gera

09124

Cagliari

06156

Perugia

08013

Barcelona

08028

Barcelona

01004

Alava

08035

Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00914693 - EU/LA Pearl Index Study - Transdermal Contraceptive Patch | Biotech Hunter | Biotech Hunter